Detection of Right Ventricular Dysfunction by Portal Vein Doppler After Cardiac Surgery (DVDDP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04890860 |
Recruitment Status :
Recruiting
First Posted : May 18, 2021
Last Update Posted : June 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postoperative Complications Heart Diseases Heart Failure Heart Valve Diseases | Other: cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass | Not Applicable |
In cardiac surgical patients, RV dysfunction is associated with organ hypoperfusion and venous congestion leading to increased morbidity and mortality.
Non-invasive methods used to assess RV function are 2D-echocardiographic measurement of tricuspid annular plane systolic excursion (TAPSE), RV ejection fraction (EF), RV fractional area change (FAC), 3D assessment of RV function, tissue Doppler assessment of velocities, and magnetic resonance imaging (MRI). Though MRI is the gold standard method to assess RV function, it cannot be used in the perioperative period.
In the present prospective observational study, The investigators investigated the association between the pattern of portal venous flow and RV function as assessed by echocardiography in the postoperative period.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 70 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Detection of Right Ventricular Dysfunction by Portal Vein Doppler After Cardiac Surgery |
Actual Study Start Date : | June 15, 2021 |
Estimated Primary Completion Date : | June 15, 2022 |
Estimated Study Completion Date : | June 15, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Adults patients undergoing mitral and / or tricuspid valve surgery with cardiopulmonary bypass. |
Other: cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass |
- Right ventricular failure [ Time Frame: First 24 hours post cardiac surgery ]
- systolic dysfunction (TAPSE below 16 mm or S wave below 9.5 cm/s)
- RV fractional area change below 35%
- End-diastole diameter ratio between RV and left ventricle > 0.6
- Ratio between S and D wave or inverse D wave in supra-hepatic veins
- Portal flow measured by Doppler [ Time Frame: First 24 hours post cardiac surgery ]flow pulsatility is assessed with the formula = 100 x (Vmax-Vmin)/Vmax. Time frame: First 24 hours post cardiac surgery
- Echocardiographic acquisition [ Time Frame: First 24 hours post cardiac surgery ]
Feasability of all measurements (RV failure with the 4 criteria:
- systolic dysfunction (TAPSE below 16 mm or S wave below 9.5 cm/s)
- RV fractional area change below 35%
- End-diastole diameter ratio between RV and left ventricle > 0.6
- Ratio between S and D wave or inverse D wave in supra-hepatic veins)
- Echocardiographic acquisition [ Time Frame: First 24 hours post cardiac surgery ]Feasability of all measurements (RV failure with the portal flow with Doppler)
- Concordance of pulsatile flow assessment [ Time Frame: First 24 hours post cardiac surgery ]Concordance of repeated measurements of the venous portal flow Time frame: First 24 hours post cardiac surgery
- Concordance of RV dysfunction measurements [ Time Frame: First 24 hours post cardiac surgery ]
Concordance of repeated measurements of :
- systolic dysfunction (TAPSE below 16 mm or S wave below 9.5 cm/s)
- RV fractional area change below 35%
- End-diastole diameter ratio between RV and left ventricle > 0.6
- Ratio between S and D wave or inverse D wave in supra-hepatic veins
- Preoperative RV dysfunction [ Time Frame: 30 days before cardiac surgery ]
As defined
- systolic dysfunction (TAPSE below 16 mm or S wave below 9.5 cm/s)
- RV fractional area change below 35%
- End-diastole diameter ratio between RV and left ventricle > 0.6
- Ratio between S and D wave or inverse D wave in supra-hepatic veins
- Acute kidney injury [ Time Frame: one week after surgery ]defined by KDIGO criteria as creatininemia elevation above > 26 micromol/L during the first 48 hours or +50% during the first week, oliguria with urine output less than 0.5 mL/kg/h during 6 hours.
- Cholestasis [ Time Frame: one week after surgery ]Conjugate bilirubin elevation above 12 mmol/L

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- More than 18 years old
- Ability to provide an informed consent
- Planned mitral and / or tricuspid valve surgery under cardiopulmonary bypass.
Exclusion Criteria:
- Insufficient echogenicity

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04890860
France | |
CMC Ambroise Paré | Recruiting |
Neuilly-sur-Seine, France, 92200 | |
Contact: NGUYEN Lee, MD,PhD +33 1 46 41 50 79 recherche@clinique-a-pare.fr |
Responsible Party: | CMC Ambroise Paré |
ClinicalTrials.gov Identifier: | NCT04890860 |
Other Study ID Numbers: |
2020/08 |
First Posted: | May 18, 2021 Key Record Dates |
Last Update Posted: | June 28, 2021 |
Last Verified: | June 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cardiac surgery Echocardiography Right ventricular dysfunction |
Doppler Portal vein Doppler Ventricular function |
Heart Diseases Ventricular Dysfunction Heart Valve Diseases Ventricular Dysfunction, Right |
Postoperative Complications Cardiovascular Diseases Pathologic Processes |